Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$9.47
-0.2%
$10.59
$9.15
$16.91
$17.14B0.32297,492 shs403,828 shs
Alexion Pharmaceuticals, Inc. stock logo
ALXN
Alexion Pharmaceuticals
$182.50
$182.82
$99.91
$187.45
$40.34B1.253.31 million shs10 shs
BeiGene, Ltd. stock logo
BGNE
BeiGene
$144.12
+3.7%
$154.68
$126.97
$266.67
$13.78B0.61257,433 shs215,587 shs
Genmab A/S stock logo
GMAB
Genmab A/S
$28.47
-0.3%
$29.46
$26.32
$42.72
$18.83B0.99587,386 shs456,119 shs
Genmab A/S stock logo
GNMSF
Genmab A/S
$279.60
-3.7%
$293.26
$262.00
$426.50
$18.28B1.011,012 shs1,217 shs
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
-0.42%-0.11%-13.30%-17.61%-36.96%
Alexion Pharmaceuticals, Inc. stock logo
ALXN
Alexion Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
BeiGene, Ltd. stock logo
BGNE
BeiGene
+3.69%+9.30%-6.37%-12.65%-41.60%
Genmab A/S stock logo
GMAB
Genmab A/S
-0.32%-0.21%-5.04%+1.14%-30.75%
Genmab A/S stock logo
GNMSF
Genmab A/S
-3.70%-0.51%-7.29%+1.30%-31.69%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Alexion Pharmaceuticals, Inc. stock logo
ALXN
Alexion Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
BeiGene, Ltd. stock logo
BGNE
BeiGene
2.7045 of 5 stars
4.42.00.00.01.91.70.6
Genmab A/S stock logo
GMAB
Genmab A/S
3.2274 of 5 stars
3.23.00.00.02.90.03.1
Genmab A/S stock logo
GNMSF
Genmab A/S
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
2.00
HoldN/AN/A
Alexion Pharmaceuticals, Inc. stock logo
ALXN
Alexion Pharmaceuticals
N/AN/AN/AN/A
BeiGene, Ltd. stock logo
BGNE
BeiGene
2.78
Moderate Buy$250.1373.56% Upside
Genmab A/S stock logo
GMAB
Genmab A/S
2.38
Hold$48.5070.35% Upside
Genmab A/S stock logo
GNMSF
Genmab A/S
N/AN/AN/AN/A

Current Analyst Ratings

Latest ALXN, ALPMY, GNMSF, GMAB, and BGNE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/24/2024
BeiGene, Ltd. stock logo
BGNE
BeiGene
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$235.00 ➝ $236.00
4/8/2024
BeiGene, Ltd. stock logo
BGNE
BeiGene
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$179.30 ➝ $164.30
4/4/2024
Genmab A/S stock logo
GMAB
Genmab A/S
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
3/27/2024
BeiGene, Ltd. stock logo
BGNE
BeiGene
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Perform ➝ Market Perform$196.00 ➝ $161.00
3/27/2024
Genmab A/S stock logo
GMAB
Genmab A/S
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
3/26/2024
Genmab A/S stock logo
GMAB
Genmab A/S
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingUnderweight ➝ Underweight
3/26/2024
Genmab A/S stock logo
GMAB
Genmab A/S
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
3/19/2024
BeiGene, Ltd. stock logo
BGNE
BeiGene
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$184.00 ➝ $186.00
3/6/2024
Genmab A/S stock logo
GMAB
Genmab A/S
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
2/27/2024
BeiGene, Ltd. stock logo
BGNE
BeiGene
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$350.00 ➝ $345.00
2/23/2024
Genmab A/S stock logo
GMAB
Genmab A/S
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$46.00 ➝ $48.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$11.24B1.52$1.35 per share7.02$6.27 per share1.51
Alexion Pharmaceuticals, Inc. stock logo
ALXN
Alexion Pharmaceuticals
$6.07B6.65$22.81 per share8.00$53.24 per share3.43
BeiGene, Ltd. stock logo
BGNE
BeiGene
$2.46B5.61N/AN/A$37.10 per share3.88
Genmab A/S stock logo
GMAB
Genmab A/S
$2.39B7.87$1.22 per share23.37$6.95 per share4.10
Genmab A/S stock logo
GNMSF
Genmab A/S
$2.39B7.64$12.30 per share22.73$59.44 per share4.70

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$742MN/A24.3618.941.370.08%6.39%3.29%N/A
Alexion Pharmaceuticals, Inc. stock logo
ALXN
Alexion Pharmaceuticals
$603.40M$11.6059.6413.150.9310.89%23.43%15.06%N/A
BeiGene, Ltd. stock logo
BGNE
BeiGene
-$881.71M-$8.50N/AN/AN/A-35.86%-23.12%-15.32%5/2/2024 (Estimated)
Genmab A/S stock logo
GMAB
Genmab A/S
$631.91M$0.9629.6619.772.0826.50%18.06%16.13%5/2/2024 (Confirmed)
Genmab A/S stock logo
GNMSF
Genmab A/S
$631.91M$9.6329.03N/A26.50%18.06%16.13%N/A

Latest ALXN, ALPMY, GNMSF, GMAB, and BGNE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024N/A
Genmab A/S stock logo
GMAB
Genmab A/S
$0.16N/A-$0.16N/AN/AN/A
2/26/202412/31/2023
BeiGene, Ltd. stock logo
BGNE
BeiGene
-$3.61-$3.53+$0.08-$3.53$632.52 million$634.40 million
2/14/2024Q4 2023
Genmab A/S stock logo
GMAB
Genmab A/S
$0.34$0.36+$0.02$0.58$678.14 million$675.29 million
2/14/2024Q4 2023
Genmab A/S stock logo
GNMSF
Genmab A/S
N/A$3.63+$3.63$5.85N/A$675.29 million
2/5/2024Q3 2024
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
N/A$0.12+$0.12$0.17N/A$2.86 billion

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$0.333.48%N/AN/AN/A
Alexion Pharmaceuticals, Inc. stock logo
ALXN
Alexion Pharmaceuticals
N/AN/AN/AN/AN/A
BeiGene, Ltd. stock logo
BGNE
BeiGene
N/AN/AN/AN/AN/A
Genmab A/S stock logo
GMAB
Genmab A/S
N/AN/AN/AN/AN/A
Genmab A/S stock logo
GNMSF
Genmab A/S
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
0.31
0.91
0.71
Alexion Pharmaceuticals, Inc. stock logo
ALXN
Alexion Pharmaceuticals
0.19
4.52
3.96
BeiGene, Ltd. stock logo
BGNE
BeiGene
0.06
2.32
2.09
Genmab A/S stock logo
GMAB
Genmab A/S
N/A
13.34
13.32
Genmab A/S stock logo
GNMSF
Genmab A/S
N/A
13.34
13.32

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
N/A
Alexion Pharmaceuticals, Inc. stock logo
ALXN
Alexion Pharmaceuticals
82.94%
BeiGene, Ltd. stock logo
BGNE
BeiGene
48.55%
Genmab A/S stock logo
GMAB
Genmab A/S
7.07%
Genmab A/S stock logo
GNMSF
Genmab A/S
N/A

Insider Ownership

CompanyInsider Ownership
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
N/A
Alexion Pharmaceuticals, Inc. stock logo
ALXN
Alexion Pharmaceuticals
4.03%
BeiGene, Ltd. stock logo
BGNE
BeiGene
7.40%
Genmab A/S stock logo
GMAB
Genmab A/S
1.54%
Genmab A/S stock logo
GNMSF
Genmab A/S
1.54%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
14,4841.81 billionN/ANot Optionable
Alexion Pharmaceuticals, Inc. stock logo
ALXN
Alexion Pharmaceuticals
3,837221.02 millionN/AOptionable
BeiGene, Ltd. stock logo
BGNE
BeiGene
10,60095.64 million88.56 millionOptionable
Genmab A/S stock logo
GMAB
Genmab A/S
2,204661.23 million651.05 millionOptionable
Genmab A/S stock logo
GNMSF
Genmab A/S
2,20465.37 millionN/ANot Optionable

ALXN, ALPMY, GNMSF, GMAB, and BGNE Headlines

SourceHeadline
Genmab A/S (OTCMKTS:GNMSF) Shares Cross Below Two Hundred Day Moving Average of $301.42Genmab A/S (OTCMKTS:GNMSF) Shares Cross Below Two Hundred Day Moving Average of $301.42
americanbankingnews.com - April 20 at 3:34 AM
Genmab Acquires A Missing Piece For Its PipelineGenmab Acquires A Missing Piece For Its Pipeline
seekingalpha.com - April 16 at 5:33 PM
Genmabs Q1 Darzalex Sales By Johnson & Johnson Reach $2.692 BlnGenmab's Q1 Darzalex Sales By Johnson & Johnson Reach $2.692 Bln
markets.businessinsider.com - April 16 at 7:32 AM
Truist Financial Keeps Their Buy Rating on Genmab (GMAB)Truist Financial Keeps Their Buy Rating on Genmab (GMAB)
markets.businessinsider.com - April 9 at 5:33 PM
ProfoundBio discovers the joys of having a wealthy ownerProfoundBio discovers the joys of having a wealthy owner
benzinga.com - April 8 at 1:36 PM
Genmab to acquire ADC maker ProfoundBioGenmab to acquire ADC maker ProfoundBio
cen.acs.org - April 7 at 8:49 PM
30 Biggest Biotechnology Companies in the World30 Biggest Biotechnology Companies in the World
finance.yahoo.com - March 17 at 8:59 AM
Genmab grows up: Celebrating 25 years, CEO prepares to wield pretty good buying powerGenmab grows up: Celebrating 25 years, CEO prepares to wield 'pretty good buying power'
fiercebiotech.com - March 14 at 1:26 PM
Passing of Genmab A/S’ Annual General MeetingPassing of Genmab A/S’ Annual General Meeting
finance.yahoo.com - March 13 at 12:58 PM
Genmab: Recent Updates Support The Growth NarrativeGenmab: Recent Updates Support The Growth Narrative
seekingalpha.com - February 21 at 5:40 AM
4 Analysts Assess Genmab: What You Need To Know4 Analysts Assess Genmab: What You Need To Know
markets.businessinsider.com - February 20 at 1:00 PM
Genmab A/S’ New Regulation Risk – A Cause for Worry?Genmab A/S’ New Regulation Risk – A Cause for Worry?
msn.com - February 15 at 12:38 PM
Genmab A/S (NASDAQ:GMAB) Q4 2023 Earnings Call TranscriptGenmab A/S (NASDAQ:GMAB) Q4 2023 Earnings Call Transcript
finance.yahoo.com - February 15 at 12:38 PM
Notice to Convene the Annual General Meeting of Genmab A/SNotice to Convene the Annual General Meeting of Genmab A/S
finance.yahoo.com - February 15 at 7:38 AM
Genmab Files Annual Report with the U.S. Securities and Exchange CommissionGenmab Files Annual Report with the U.S. Securities and Exchange Commission
finance.yahoo.com - February 14 at 4:15 PM
Genmab: Growth Is Still a Better ChoiceGenmab: Growth Is Still a Better Choice
finance.yahoo.com - February 14 at 4:15 PM
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical CancerTisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
finance.yahoo.com - February 2 at 7:26 AM
Cracking The Code: Understanding Analyst Reviews For GenmabCracking The Code: Understanding Analyst Reviews For Genmab
markets.businessinsider.com - January 29 at 8:44 AM
Grant of Restricted Stock Units and Warrants to Employees in GenmabGrant of Restricted Stock Units and Warrants to Employees in Genmab
finance.yahoo.com - January 25 at 5:23 PM
Genmab Announces Decision in Arbitration Appeal under License Agreement with JanssenGenmab Announces Decision in Arbitration Appeal under License Agreement with Janssen
finance.yahoo.com - January 22 at 7:38 PM
J&J, Genmab Unveil Darzalex Faspro Data with Eye Toward Earlier Multiple Myeloma LinesJ&J, Genmab Unveil Darzalex Faspro Data with Eye Toward Earlier Multiple Myeloma Lines
biospace.com - December 13 at 2:07 PM
HRMY or GMAB: Which Is the Better Value Stock Right Now?HRMY or GMAB: Which Is the Better Value Stock Right Now?
finance.yahoo.com - December 7 at 2:14 PM
Genmab A/S (NASDAQ:GMAB) Q3 2023 Earnings Call TranscriptGenmab A/S (NASDAQ:GMAB) Q3 2023 Earnings Call Transcript
finance.yahoo.com - November 8 at 7:38 PM
Genmab reports 9M resultsGenmab reports 9M results
msn.com - November 7 at 6:13 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Astellas Pharma logo

Astellas Pharma

OTCMKTS:ALPMY
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.
Alexion Pharmaceuticals logo

Alexion Pharmaceuticals

NASDAQ:ALXN
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
BeiGene logo

BeiGene

NASDAQ:BGNE
BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.
Genmab A/S logo

Genmab A/S

NASDAQ:GMAB
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Genmab A/S logo

Genmab A/S

OTCMKTS:GNMSF
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.